drugset / Trial / NCT01161498

Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer

NCT01161498

Phase 3 Terminated 5 enrolled BioVex Limited Amgen · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is being conducted to learn about the safety and risks of using talimogene laherparepvec to treat patients with head and neck cancer and to see if talimogene laherparepvec and chemoradiation together can destroy the tumours versus the use of chemoradiation alone. This study may provide information on the usefulness of talimogene laherparepvec combined with chemoradiation as a future treatment for head and neck cancer.

Timeline

Start
2011-02
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Talimogene Laherparepvec Other / unclassified 8 ml Other
Background Cisplatin Other / unclassified 100 mg/m2 Intravenous